Review
Management of disseminated kidney cancer
Affiliations
- PMID: 7974894
Item in Clipboard
Review
Management of disseminated kidney cancer
Urol Clin North Am.
1994 Nov.
Abstract
The approach to disseminate renal cell carcinoma (RCC) has evolved significantly in recent years, largely owing to the progress of biologic therapy development. With increasing knowledge of biologic therapy come several dilemmas, including the choice of cytokine therapy, the appropriate mode of delivery, the selection of candidates for given therapeutic options, and the role of cytoreductive nephrectomy in immunotherapy protocols. This article reviews the historical development of immunotherapy and the lessons learned from previous experience and offers a logical approach to the patient with disseminated RCC.
Similar articles
-
Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.Curr Opin Support Palliat Care. 2009 Sep;3(3):157-65. doi: 10.1097/SPC.0b013e32832e466b. Curr Opin Support Palliat Care. 2009. PMID: 19528804 Review.
-
Cytoreductive nephrectomy in metastatic renal cell carcinoma.Curr Opin Urol. 2008 Sep;18(5):474-80. doi: 10.1097/MOU.0b013e32830a4f21. Curr Opin Urol. 2008. PMID: 18670270 Review.
-
Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.Semin Urol Oncol. 1996 Nov;14(4):230-6. Semin Urol Oncol. 1996. PMID: 8946623
-
Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.Urol Oncol. 2009 Nov-Dec;27(6):598-603. doi: 10.1016/j.urolonc.2008.07.023. Epub 2008 Sep 25. Urol Oncol. 2009. PMID: 18818106
-
Current surgical approaches, nephron-sparing surgery, and the role of surgery in the integrated immunologic approach to renal-cell carcinoma.Semin Oncol. 1995 Feb;22(1):29-33. Semin Oncol. 1995. PMID: 7855616 Review. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Medical